BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37722356)

  • 1. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL.
    Tam C; Pinilla-Ibarz J; Castillo CG; Fenili AC; Huntley K; Karakus V; Mattar M; Miroli MA; Moura C; Pavlovsky M; Piotrowski F; Šimkovič M; Stilgenbauer S
    Blood Adv; 2023 Nov; 7(22):6819-6828. PubMed ID: 37722356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research].
    Xu W; Yi SH; Feng R; Wang X; Jin J; Mi JQ; Ding KY; Yang W; Niu T; Wang SY; Zhou KS; Peng HL; Huang L; Liu LH; Ma J; Luo J; Su LP; Bai O; Liu L; Li F; He PC; Zeng Y; Gao D; Jiang M; Wang JS; Yao HX; Qiu LG; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):380-387. PubMed ID: 37550187
    [No Abstract]   [Full Text] [Related]  

  • 3. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education.
    Rocque GB; Williams CP; Halilova KI; Borate U; Jackson BE; Van Laar ES; Pisu M; Butler TW; Davis RS; Mehta A; Knight SJ; Safford MM
    Transl Behav Med; 2018 Mar; 8(2):175-182. PubMed ID: 29390159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
    Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
    Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
    Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
    Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
    Nabhan C; Mato A; Flowers CR; Grinblatt DL; Lamanna N; Weiss MA; Davids MS; Swern AS; Bhushan S; Sullivan K; Flick ED; Kiselev P; Sharman JP
    BMC Cancer; 2017 Mar; 17(1):198. PubMed ID: 28302090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries.
    Bird ST; Tian F; Flowers N; Przepiorka D; Wang R; Jung TH; Kessler Z; Woods C; Kim B; Miller BW; Wernecke M; Kim C; McKean S; Gelperin K; MaCurdy TE; Kelman JA; Graham DJ
    JAMA Oncol; 2020 Feb; 6(2):248-254. PubMed ID: 31855259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States.
    Kabadi SM; Goyal RK; Nagar SP; Kaye JA; Davis KL
    Cancer Med; 2019 Jul; 8(8):3803-3810. PubMed ID: 31144473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR).
    Takizawa J; Izutsu K; Nagai H; Fukase K; Nakamura M; Jinushi M; Suzumiya J
    J Clin Exp Hematop; 2021 Sep; 61(3):126-134. PubMed ID: 34092721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
    Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
    Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
    Shadman M
    JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second cancers in patients with chronic lymphocytic leukemia.
    Travis LB; Curtis RE; Hankey BF; Fraumeni JF
    J Natl Cancer Inst; 1992 Sep; 84(18):1422-7. PubMed ID: 1512794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy.
    Montserrat E; Bosch F; Rozman C
    Ann Oncol; 1997; 8 Suppl 1():93-101. PubMed ID: 9187440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.